اخبار و اعلانات

 آمار

تعداد نشریات24
تعداد شماره‌ها851
تعداد مقالات7,575
تعداد مشاهده مقاله13,413,800
تعداد دریافت فایل اصل مقاله11,580,478
Boustan, Arad, Mosaffa, Fatemeh, Jahangiri, Rosa, Heidarian-Miri, Hamid, Dahmardeh-Ghalehno, Asefeh, Jamialahmadi, Khadijeh. (1400). Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer. , 10(3), 109-119. doi: 10.22099/mbrc.2021.39878.1597
Arad Boustan; Fatemeh Mosaffa; Rosa Jahangiri; Hamid Heidarian-Miri; Asefeh Dahmardeh-Ghalehno; Khadijeh Jamialahmadi. "Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer". , 10, 3, 1400, 109-119. doi: 10.22099/mbrc.2021.39878.1597
Boustan, Arad, Mosaffa, Fatemeh, Jahangiri, Rosa, Heidarian-Miri, Hamid, Dahmardeh-Ghalehno, Asefeh, Jamialahmadi, Khadijeh. (1400). 'Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer', , 10(3), pp. 109-119. doi: 10.22099/mbrc.2021.39878.1597
Boustan, Arad, Mosaffa, Fatemeh, Jahangiri, Rosa, Heidarian-Miri, Hamid, Dahmardeh-Ghalehno, Asefeh, Jamialahmadi, Khadijeh. Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer. , 1400; 10(3): 109-119. doi: 10.22099/mbrc.2021.39878.1597

Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer

Molecular Biology Research Communications
دوره 10، شماره 3، 2021، صفحه 109-119    اصل مقاله (799.93 K)
نوع مقاله: Original article
شناسه دیجیتال (DOI): 10.22099/mbrc.2021.39878.1597
نویسندگان
Arad Boustan1؛ Fatemeh Mosaffa2، 3؛ Rosa Jahangiri1؛ Hamid Heidarian-Miri4؛ Asefeh Dahmardeh-Ghalehno3؛ Khadijeh Jamialahmadi* 2
1Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4Department of Epidemiology, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Despite the discovery of a number of different mechanisms underlying tamoxifen resistance, its molecular pathway is not completely clear. The upregulation of SALL4 and Nodal has been reported in breast cancer. Nevertheless, their role in tamoxifen resistance has not been investigated. In the present study, we compared Nodal and SALL4 expression in 72 tamoxifen sensitive (TAMS) and tamoxifen-resistant (TAMR) patients. Afterward, the correlation of expression data with clinicopathological features and survival of patients was studied. Results showed that both SALL4 and Nodal were significantly upregulated in TAMR compared to TAMS patients. Besides, there was a positive association between Nodal and SALL4 expression. Furthermore, we evaluated their correlation with the expression of Oct4, Nanog and Sox2 stemness markers. The results demonstrated that in most tissue samples there was a positive correlation between Nodal and SALL4 expression with these stemness markers. Besides, the overexpression of SALL4 and Nodal significantly correlated with the N stage. Moreover, the overexpression of SALL4 was associated with extracapsular invasion and lymphatic invasion. High level expressions of SALL4 and Nodal had a significant association with worse disease-free survival (DFS) rates. In addition, increased level of Nodal expression provides a superior predictor factor for DFS. The multivariate Cox regression analysis also revealed that for DFS, perineural invasion (PNI) was independently an unfavorable prognostic value. These findings suggest that the high expression of SALL4 and Nodal could contribute to tamoxifen resistance and worse survival rates in tamoxifen-treated ER+ breast cancer patients.
کلیدواژه‌ها
Breast Cancer؛ Tamoxifen Resistance؛ SALL4؛ Nodal؛ Epithelial to Mesenchymal Transition (EMT)؛ Cancer Stem Cell (CSC)
مراجع
  1. Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. Asian Pac J Cancer Prev 2019;20:2015-2020.
  2. Dolatkhah R, Somi MH, Jafarabadi MA, Hosseinalifam M, Sepahi S, Belalzadeh M, Nezamdoust M, Dastgiri S. Breast cancer survival and incidence: 10 years cancer registry data in the northwest, Iran. Int J Breast Cancer 2020;2020:1963814.
  3. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:e48-72.
  4. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980-1989.
  5. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525-530.
  6. Chang M. Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) 2012; 20:256-267.
  7. Zhu J, Zou Z, Nie P, Kou X, Wu B, Wang S, Song Z, He J. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis 2016;7:e2454.
  8. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-1428.
  9.      9.Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol 2012; 44:2144-2151.
  10.    10.Wang SS, Jiang J, Liang XH, Tang YL. Links between cancer stem cells and epithelial-mesenchymal transition. Onco  Targets Ther 2015;8:2973-2980.
  11. Tatetsu H, Kong NR, Chong G, Amabile G, Tenen DG, Chai L. SALL4, the missing link between stem cells, development and cancer. Gene 2016;584:111-119.
  12. Yang J, Chai L, Gao C, Fowles TC, Alipio Z, Dang H, Xu D, Fink LM, Ward DC, Ma Y. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood 2008; 112:805-813.
  13. Chen YY, Li ZZ, Ye YY, Xu F, Niu RJ, Zhang HC, Zhang YJ, Liu YB, Han BS. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride. BMC Mol Biol 2016;17:6.
  14. Vallier L, Mendjan S, Brown S, Chng Z, Teo A, Smithers LE, Trotter MW, Cho CH, Martinez A, Rugg-Gunn P, Brons G, Pedersen RA. Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development 2009;136:1339-1349.
  15. Fang R, Zhang G, Guo Q, Ning F, Wang H, Cai S, Du J. Nodal promotes aggressive phenotype via Snail-mediated epithelial-mesenchymal transition in murine melanoma. Cancer Lett 2013;333:66-75.
  16. Bodenstine TM, Chandler GS, Seftor RE, Seftor EA, Hendrix MJ. Plasticity underlies tumor progression: role of Nodal signaling. Cancer Metastasis Rev 2016;35:21-39.
  17. Jahangiri R, Mosaffa F, EmamiRazavi A, Gharib M, Jamialahmadi K. Increased expression of Gankyrin and stemness factor Oct-4 are Associated with Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients. Pathol Oncol Res 2020; 26:1921-1934.
  18. Guo C, Liu S, Wang J, Sun MZ, Greenaway FT. ACTB in cancer. Clin Chim Acta 2013;417:39-44.
  19. Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Lee YC, Cheng YY, Liu LW, Wei HW, Lee HM. Nodal promotes growth and invasion in human gliomas. Oncogene 2010;29:3110-3123.
  20. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010;177:1087-1094.
  21. Zhang X, Yuan X, Zhu W, Qian H, Xu W. SALL4: an emerging cancer biomarker and target. Cancer Lett 2015;357:55-62.
  22. Chen T, Tsang JYS, Su XC, Li P, Sun WQ, Wong ILK, Choy KY, Yang Q, Tse GMK, Chan TH, Chow LMC. SALL4 promotes tumor progression in breast cancer by targeting EMT. Mol Carcinog 2020;59:1209-1226.
  23. Wu Q, Chen X, Zhang J, Loh YH, Low TY, Zhang W, Zhang W, Sze SK, Lim B, Ng HH. Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. J Biol Chem 2006;281:24090-24094.
  24. Liu A, Cheng L, Du J, Peng Y, Allan RW, Wei L, Li J, Cao D. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol 2010;34:697-706.
  25.    25.Yanagihara N, Kobayashi D, Kuribayashi K, Tanaka M, Hasegawa T, Watanabe N. Significance of SALL4 as a drug‑resistant factor in lung cancer. Int J Oncol 2015;46:1527-1534.
  26.    26.Yue X, Xiao L, Yang Y, Liu W, Zhang K, Shi G, Zhou H, Geng J, Ning X, Wu J, Zhang Q. High cytoplasmic expression of SALL4 predicts a malignant phenotype and poor prognosis of breast invasive ductal carcinoma. Neoplasma 2015;62:980-988.
  27. Duan W, Li R, Ma J, Lei J, Xu Q, Jiang Z, Nan L, Li X, Wang Z, Huo X, Han L, Wu Z, Wu E, Ma Q. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Oncotarget 2015;30:1490-1506.
  28. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E, Hidalgo M, Cebrián DÁ, Heuchel R, Löhr M, Berger F, Bartenstein P, Aicher A, Heeschen C. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011;9:433-446.
  29. Strizzi L, Postovit LM, Margaryan NV, Seftor EA, Abbott DE, Seftor RE, Salomon DS, Hendrix MJ. Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis 2008;29:91-103.
  30.    30.Vo BT, Khan SA. Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. Prostate 2011;71:1084-1096.
  31. Gong Y, Guo Y, Hai Y, Yang H, Liu Y, Yang S, Zhang Z, Ma M, Liu L, Li Z, He Z. Nodal promotes the self-renewal of human colon cancer stem cells via an autocrine manner through Smad2/3 signaling pathway. Biomed Res Int 2014;2014:3641.
  32. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJ. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res 2012;14:R75.
آمار
تعداد مشاهده مقاله: 1,308
تعداد دریافت فایل اصل مقاله: 728


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب